Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Galderma Announces Record Sales for the First Nine Months of 2024 - Beauty Packaging

What are you searching for?

Sign in
Beauty Industry, Mergers and Acquisitions

Galderma Announces Record Sales for the First Nine Months of 2024

Net sales reach $3.259 billion, up 9.2% from last year.

Author Image

By: Rachel Klemovitch

Assistant Editor

Galderma Group AG has announced its sales performance for the first nine months of 2024, reporting record net sales, of $3.259 billion, a growth of 9.2 % compared to last year.
 
Flemming Ørnskov, M.D., MPH, CEO of Galderma stated,
 
“By executing on our unique Integrated Dermatology Strategy, Galderma continues its strong growth trajectory, driven by momentum behind our science-based premium brands. The exciting progress with our late-stage pipeline with key regulatory approvals and differentiated innovations positions Galderma for continued strong growth. Combined with our high-performing commercial execution and increasing penetration in existing and new key markets, this sets the stage for further growth acceleration and value creation.”
 
Net sales growth was widespread across product categories and geographies. All product categories grew, with notable sustained double-digit growth in Injectable Aesthetics and Dermatological Skincare.
 
Continued performance across all product categories with constant currency year-on-year growth of 10.6% for Injectable Aesthetics, 10.6% for Dermatological Skincare, and 2.9% for Therapeutic Dermatology for the first nine months of 2024. 
 
Net sales in Injectables Aesthetics reached $1,698 million. Dermatological Skincare’s net sales were $990 million, with growth driven by its Cetaphil and Alastin brands. Therapeutic Dermatology net sales reached $571 million. 
 
Galderma expects full-year net sales growth to be in the range of 8.8-9.5% year-on-year at constant currency. It was previously expected towards the upper end of the 7-10% growth range at constant currency. 

Read Next

L’Oréal Acquires 10% Stake in Galderma

Galderma Reports Net Sales of Over $1 Billion in Q1 and 12.4% Year-on-Year Growth
 

Add us as a preferred source on Google

Get the latest Beauty Packaging news, insights and analysis in your Google Search and AI experiences.

Add Beauty Packaging as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Beauty Packaging Newsletters

Topics